Clarivate Plc (CLVT) Q3 2026 earnings review
Clarivate closes its healthcare sale, and subscription growth speeds up
Clarivate closed the sale of its healthcare division early and lifted subscription growth, while one-off sales kept shrinking. Continuing sales from businesses owned a year ago edged up 0.4% as recurring revenue rose 1.3% and annual contract value grew 1.8%. Chief executive Matti Shem Tov said the patent division returned to contract growth, and dropping lower-margin products lifted the continuing operating profit margin to 45%.
| Continuing sales from businesses owned a year ago | +0.4% recurring sales +1.3% |
|---|---|
| Annual contract value growth (underlying) | +1.8% +1.5% last quarter |
| Continuing Adjusted EBITDA margin | 45.3% 41.9% a year ago |
| Full-year free cash flow outlook | Cut to $320–340M from $365M floor after healthcare sale |
⚖️ Verdict: 🟢 Bullish
The story got better because the $488 million healthcare sale closed in October and contract value growth turned back up after two slower quarters. That cash removes the balance-sheet risk around the 2028 debt maturities, and the patent unit's underlying revenue drop narrowed to almost zero. One caution: removing the healthcare unit and paying deal fees cut the full-year free cash flow plan to a $330 million middle.
The question now is whether recurring sales can hit the fourth-quarter target of 2% to 2.5% growth through new demand rather than just price increases and customers switching from one-off purchases. If new AI tools drive genuine volume, total underlying sales will speed up alongside recurring revenue; if customers only switch contract types, one-off declines will keep offsetting subscription gains. Fourth-quarter segment and transaction tables will settle it.
🐂 Bull Case
Healthcare Sale Closed Early With $488 Million
Clarivate provides research databases for universities and patent tools for corporate legal teams. In October the data provider completed the "early close of the Life Sciences & Healthcare segment divestiture", chief executive Matti Shem Tov said, bringing in $488.4 million in net cash after the quarter ended.
- Total debt at September 30: $4.18 billion, down $293.8 million from the end of 2025
- Debt retired this year: $100 million of 2026 notes paid off and $192.6 million of 2028 and 2029 notes bought back at a 5% discount
- Net debt after healthcare sale cash: $3.43 billion by our math, or 3.9 times full-year continuing operating profit before depreciation
Closing the sale removes the risk that the deal would fall through and strand the balance sheet plan. Quarterly interest costs already fell 11% from a year ago to $61.0 million, and applying the $488.4 million of sale cash will cut interest bills again next year.
What to watch: the exact amount of 2028 and 2029 bonds retired with the sale cash in the fourth-quarter report. Retiring the full $488 million at par or a discount will show whether net debt drops toward management's long-term goal.
Dropping One-Off Sales Lifted Continuing Profit Margins
Selling the healthcare unit and winding down one-off book sales left the British-based group smaller but more profitable. Recurring revenue — annual subscriptions and patent renewal fees — now makes up 92.2% of continuing sales, up from 83.2% a year ago by our math.
Operating profit before depreciation and one-offs (Adjusted EBITDA) in the continuing business reached 45.3% of sales, up 3.4 percentage points from a year ago. The direct cost of delivering products and data fell 4.8 percentage points of revenue to 28.9%, while overhead and sales costs rose 0.5 percentage points to 27.9%.
What to watch: fourth-quarter continuing Adjusted EBITDA margin against the 44% to 46% outlook range. Staying above 45% after the healthcare unit leaves will prove that separating the business did not leave behind large shared overhead costs.
Contract Value Growth Turned Up on Patent Tools
"Third quarter results continued to improve across key metrics, including organic recurring revenue growth and the return to positive ACV growth in the Intellectual Property segment," Shem Tov said. Annualized contract value (ACV) is the yearly value of active subscription contracts. Shem Tov also credited "AI-led innovation" as Clarivate brings trademark data into Microsoft Copilot through IPOne, its patent and trademark software.
Continuing ACV from businesses owned a year ago rose 1.8%, after slowing in the prior two quarters. Patent and trademark renewal sales rose 0.7%, lifting the Intellectual Property unit's underlying revenue to a 0.4% decline after a 2.3% drop in the second quarter. Still, the company noted that the ACV gain was "primarily driven by improved product pricing" rather than higher sales volume.
What to watch: Intellectual Property underlying revenue growth in the fourth quarter. A positive reading will meet management's promise that the patent division would return to growth by the end of 2026.
🐻 Bear Case
Healthcare Sale and Deal Costs Cut Cash Flow
Finance chief Michael Easton said his focus remains on "translating organic growth into sustainable earnings and free cash flow, while maintaining a disciplined approach to capital allocation". Three months ago the company kept its full-year free cash flow target at $365 million to $435 million, pointing to the bottom of that range.
This quarter Clarivate cut the full-year free cash flow plan to $320 million to $340 million. Removing the sold healthcare division for the fourth quarter accounts for part of the drop, but full-year deal fees also rose to $35 million and restructuring charges reached $30 million. Free cash flow fell 4.6% from a year ago in the third quarter to $110.2 million, even after capital spending dropped by $10.2 million.
What to watch: fourth-quarter free cash flow against the $85 million to $105 million plan. Landing near the $95 million middle of the range will show whether one-off deal fees have finished draining cash.
One-Off Sales Drop Offsets Subscription Gains
Clarivate wants investors to focus on its recurring subscription contracts, which grew 1.3% on an underlying basis and added $5.7 million of sales this quarter. Total continuing revenue from businesses owned a year ago grew only 0.4%, because one-off transactional sales fell 12.4%, or $3.9 million.
The company said the one-off drop came in part from "customer migration to higher margin subscription products as we focus on our recurring revenues". When an existing customer switches from a one-off purchase to a subscription, recurring sales rise while one-off sales fall by a similar amount. That shift improves predictability, but it explains why total underlying growth has stayed below 1% all year.
What to watch: fourth-quarter recurring underlying growth against the 2.0% to 2.5% plan, set beside one-off transactional sales. If recurring sales reach 2.25% only because more customers switch from one-off purchases, total underlying revenue will barely grow.
Risks this quarter didn't answer
Four standing concerns received no numbers in the third-quarter earnings release and remain open until the quarterly filing or conference call.
- AI product revenue: management praised commercial traction for its AI tools, but gave no customer count or contract value.
- Third-party AI chat economics: Clarivate is putting trademark data inside Microsoft Copilot, without stating whether customers pay extra per query or get it free inside existing subscriptions.
- University and government budgets: the Academia & Government unit now makes up 60% of sales, and the release gave no update on US federal funding pressure.
- Shareholder lawsuits: any update on the 2021 accounting restatement cases waits for the legal footnote in the quarterly filing.
💲 Other KPIs
Up 3.2% from $737.4 million at the end of 2025, while net accounts receivable rose 7.3% to $747.4 million. Deferred revenue is cash customers have paid upfront for subscriptions not yet delivered, so its steady climb supports the 1.5% underlying subscription revenue growth recorded in the third quarter.
Up 16.7% from $0.18 a year ago, including the healthcare unit in both periods. Diluted shares excluding one-offs fell 4.7% from a year ago to 643.6 million because of last year's buybacks, while lower debt cut net interest expense by $7.5 million. On a standard accounting basis, net loss widened to $80.8 million after a $62.2 million healthcare write-down.
Down 15.5% from $65.6 million a year ago, or 9.8% of total revenue against 10.5% last year. Across the first nine months of 2026, capital spending fell 13.8% to $165.9 million, and the data group lowered its full-year capital spending plan by another $15 million to $230 million.
🔮 Guidance
Cut. Removing the sold healthcare division lowered the full-year range by half a percentage point at the middle, to 2.0%, matching the new fourth-quarter range. That 2.0% middle still requires contract value growth to speed up by 0.2 percentage points from the third quarter's 1.8% pace.
Cut. The full-year middle moved down from 1.50% to 1.25% after nine-month recurring sales grew 0.9%. To hit that full-year plan, the new fourth-quarter outlook calls for 2.00% to 2.50% recurring growth, a step up of nearly a full percentage point from the third quarter's 1.3% reading.
Cut. Clarivate narrowed the continuing revenue range and trimmed the middle by $15 million to $1.975 billion, down 4.4% from last year's continuing sales by our math. The new $500 million fourth-quarter middle is up 3.8% from the third quarter on normal year-end seasonality.
Cut. Stripping out the healthcare division for the full year reset the operating profit target to an $875 million middle, compared with $1,010 million on the old combined basis. With $645.6 million earned in the first nine months, the new fourth-quarter range of $215 million to $235 million leaves the continuing business up slightly from the third quarter's $218.2 million.
Raised. Dropping the lower-margin healthcare division lifted the full-year margin target by 1.25 percentage points at the middle to 44.0%. The fourth-quarter plan of 44.0% to 46.0% sits right around the third quarter's 45.3% continuing margin.
Unchanged at the middle. Clarivate tightened the full-year range around the same $0.75 middle, up 8.7% from 2025. Because the full-year figure keeps the healthcare unit's earnings for the first nine months and drops them in the fourth quarter, the fourth-quarter outlook of $0.14 to $0.18 steps down from $0.21 in the third quarter.
Cut. The full-year middle dropped by $70 million, and sits $35 million below the bottom of the old range. Losing fourth-quarter cash flow from the sold healthcare unit and paying higher deal and restructuring costs drove the reduction, leaving $85 million to $105 million planned for the fourth quarter.
❓ Key Questions
How are third-party AI chat integrations priced?
Clarivate is bringing CompuMark trademark data into Microsoft Copilot through IPOne. Investors need to know whether customers pay extra per query or seat, or if the integration is bundled free to stop customers from cancelling.
What do the new AI products add to contract value?
Management credits AI tools in both remaining divisions for lifting recurring growth, but has not published revenue or contract value from those products. Without a dollar figure, readers cannot separate new AI demand from routine price increases.
Will any shared overhead stay behind after the healthcare sale?
The continuing fourth-quarter margin plan of 44% to 46% is slightly below the third quarter's 45.3% level. Management has not stated whether separating the healthcare division leaves behind shared technology or administrative costs.
Which bonds will the $488.4 million sale cash pay down?
The healthcare sale closed on October 6 with $488.4 million in net cash proceeds. Retiring the 2028 and 2029 notes at a discount would cut 2027 interest expense by more than paying them off at face value.